ASX share A2 Milk Company Ltd (ASX: A2M) plunged to fresh 52-week lows on Monday. The stock initially fell as much as 18% before recovering to $6.35 in afternoon trade, still down almost 13%.
The decline followed news that the company had recalled multiple batches of infant formula sold in the US over contamination concerns.
Today's fall comes on top of an already brutal month for the ASX share. It's now down roughly 31% over the past month as investor sentiment deteriorates quickly.
Image source: Getty Images
What triggered today's sell-off?
The immediate catalyst was a voluntary recall of three batches of A2 Platinum Premium infant formula sold in the US after testing detected trace levels of a toxin known as cereulide.
This is a heat-stable toxin produced by certain strains of Bacillus cereus bacteria. The concern is that it can survive normal food processing and, in sufficient quantities, may cause vomiting and gastrointestinal illness.
While regulators and the ASX share confirmed the issue following additional testing, there have been no reported illnesses linked to the affected products.
Why the market reacted so strongly
Even though the recall is limited, investors reacted sharply for several key reasons. First is reputational risk. Infant formula is one of the most sensitive food categories globally. Even small contamination events can significantly damage consumer trust.
Second is geographic exposure. ASX share A2 Milk earns a large portion of its revenue from China, where food safety concerns are historically heightened. Any negative headlines in this category can quickly influence brand perception and demand.
Third, this is not an isolated scare. Similar cereulide-related recalls have recently affected major global players such as Nestlé SA (XSWX: NESN) and Danone SA (XPAR: BN). This has increased investor sensitivity across the sector.
More than just the recall
The share price weakness is also being driven by broader concerns around execution and earnings momentum.
In April, the ASX share downgraded its FY2026 guidance, citing ongoing supply chain disruptions. The company now expects revenue growth in the low to mid double-digit range. That's down from previous expectations of mid double-digit growth.
The company also downgraded EBITDA margins. The guidance is now at 14% to 14.5%, compared to the prior range of 15.5% to 16%. As a result, the business expects net profit after tax to be flat or slightly lower than FY2025.
These revisions reinforced investor concerns that operational challenges may be more persistent than previously anticipated.
Foolish Takeaway
The latest plunge in the ASX milk share reflects a combination of factors: a high-profile product recall, worsening sentiment around food safety risks, and already weakening financial guidance.
While underlying demand for infant formula remains solid, investors are clearly waiting for evidence that supply chain issues and execution challenges are under control before stepping back in.
